"Cancer cells have different sensitivities to the innate or adaptive response, so it is important to target both in order to eradicate it. We have developed a special type of modified [immune] cell, called aAVC [artificial adjuvant vector cells], which we found can do this. While we have so far been doing preclinical studies, we will be performing a first-in-man study in the near future."
Shin-ichiro Fujii, team leader of the Laboratory for Immunotherapy at RIKEN Center for Integrative Medical Sciences
"This round was less about capital; it was more about bringing on board solid institutional investors that could then support our public offering. We recognize it is valuable to have a group of shareholders that can instill confidence in the public market, names that are respected and recognized in that market."
Carl Firth, CEO, Aslan Pharmaceuticals Pte. Ltd., on the firm's $23 million series D financing
"A study in women who are newly diagnosed is a very provocative idea. Although we are very successful in treating the disease and getting people into remission following surgery and chemotherapy, the risk of relapse is very high. And if a woman does have a relapse, that is not a curable situation. So, if we can improve the outcomes in the start, there is a potential that we can improve the cure rates in ovary cancer."
Don Dizon, clinical co-director of gynecologic oncology at Massachusetts General Hospital Cancer Center, commenting on a phase III registration study to test the PD-L1 inhibitor avelumab in combination with or as follow-on treatment to platinum-based chemotherapy in patients with metastatic, previously untreated epithelial ovarian cancer begun by Merck KGaA and Pfizer Inc.